LYRA: Maintenance therapy with daratumumab improves depth of response and achieves durable remissions in MM patients

Bookmark and Share
Published: 17 Dec 2019
Views: 399
Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA

Dr Robert Rifkin speaks to ecancer at the 2019 ASH meeting in Orlando about the updated results of the LYRA study, which examined the effect of daratumumab maintenance therapy, following daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (CyBorD) for the treatment of multiple myeloma (MM).

Dr Rifkin gives an update on the findings of this study, in which maintenance with daratumumab monotherapy increased the complete response rate in patients with newly diagnosed and relapsed multiple myeloma. This was also associated with durable progression-free and overall survival.